What is Kerecis?
Founded in 2009 and headquartered in the Westfjords of Iceland, Kerecis specializes in the development of proprietary fish skin-based products designed to facilitate the healing of complex wounds and tissue damage. The company's core technology utilizes intact fish skin, which shares a similar structure to human skin, to provide a scaffold for cellular regeneration. This innovative approach has disrupted traditional wound management markets, offering a highly effective, biocompatible alternative to synthetic or mammalian-derived grafts. Kerecis maintains a strong market position by combining rigorous clinical validation with a scalable manufacturing process, effectively bridging the gap between marine biotechnology and modern surgical applications.
How much funding has Kerecis raised?
Kerecis has raised a total of $145M across 6 funding rounds:
Series A
$2M
Series B
$3M
Debt
$3M
Series C
$16M
Debt
$21M
Series D
$100M
Series A (2014): $2M with participation from New Business Venture Fund and EHF Capital
Series B (2016): $3M, investors not publicly disclosed
Debt (2018): $3M, investors not publicly disclosed
Series C (2019): $16M featuring Undisclosed
Debt (2020): $21M backed by Silicon Valley Bank
Series D (2022): $100M with participation from Kirkbi and Emerson Collective
Key Investors in Kerecis
Kirkbi
Kirkbi is a private holding and investment company that manages the long-term interests of the LEGO brand, focusing on sustainable investments across diverse sectors including renewable energy and strategic corporate equity.
Emerson Collective
Emerson Collective is a purpose-driven investment firm that supports innovators and entrepreneurs working to address complex societal challenges in education, economic mobility, and environmental sustainability.
Silicon Valley Bank
Silicon Valley Bank provides specialized commercial and private banking services, asset management, and financial solutions tailored to the unique needs of the innovation economy.
What's next for Kerecis?
With the recent influx of capital, Kerecis is well-positioned to scale its commercial operations and expand its footprint in international markets. The company's strategic roadmap focuses on deepening its clinical research pipeline and enhancing its manufacturing capabilities to meet the rising demand for regenerative tissue products. As the firm transitions into a more mature phase of enterprise-level operations, it is expected to prioritize the integration of its technology into standard hospital protocols, further solidifying its competitive advantage in the global healthcare landscape. The continued support from high-profile investment entities suggests a strong confidence in the company's long-term potential to redefine standards in tissue repair and patient recovery.
See full Kerecis company page
